Mediwound Ltd (MDWD)

[midastouch017]

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

https://ih.advfn.com/stock-market/NASDAQ/mediwound-MDWD/stock-news/84639471/prospectus-filed-pursuant-to-rule-424b3-424b3

March 22 2021 - 05:01PM

Edgar (US Regulatory)
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-230490
PROSPECTUS SUPPLEMENT
(To Prospectus dated April 22, 2019)

MediWound Ltd.
Ordinary Shares

This prospectus supplement updates and supplements certain information contained in the prospectus dated April 22, 2019, each of which is a part of the registration statement on Form F-3 that we previously filed with the Securities and Exchange Commission (Registration No. 333-230490). The reference to “selling shareholders” in the section entitled “Selling Shareholders” of the accompanying prospectus and footnote (5) of the table entitled “Calculation of Registration Fee” on the cover of the F-3 (Registration No. 333-230490), are hereby updated to identify the following selling shareholders and the respective ordinary shares, par value NIS 0.01 per share, held by each of them and registered for resale, namely:

(i) 8,208,973 ordinary shares held by Clal Life Sciences LP (a fully owned partnership of Clal Biotechnology Industries Ltd.), (ii) 1,180,582 ordinary shares held by Clal Biotechnology Industries Ltd., (iii) 1,710,205 ordinary shares held by L.R. Research & Development Ltd., and (iv) 140,367 ordinary shares held by Lior Rosenberg.

The selling shareholders, may offer and sell from time to time, pursuant to this prospectus supplement and the accompanying prospectus, an aggregate of up to the foregoing number of ordinary shares held by each of them.

We provide information to you in two separate documents that are bound together: (1) this prospectus supplement, which describes the specific names and holdings of the selling shareholders; and (2) the accompanying prospectus, dated April 22, 2019, which provides general information, some of which may not be relevant at this time. If information in this prospectus supplement is inconsistent with the accompanying prospectus, you should rely on this prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.